NCT04520646

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.

Conditions

• Acromegaly
• Cardiomyopathies

Interventions

Type	Name	Description
DRUG	Empagliflozin	empagliflozin of 10mg/day is added on the basis of primary care

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-08-31
• Completion: 2022-08-31
• First posted: 2020-08-20
• Last updated: 2020-08-20

Locations

1 site across 1 country: China